ID: ALA5198288

Max Phase: Preclinical

Molecular Formula: C21H20F2N2O3

Molecular Weight: 386.40

Representations

Canonical SMILES:  CCC(C)Oc1cc(NC(=O)/C(C#N)=C(/C)O)c(F)cc1-c1ccccc1F

Standard InChI:  InChI=1S/C21H20F2N2O3/c1-4-12(2)28-20-10-19(25-21(27)16(11-24)13(3)26)18(23)9-15(20)14-7-5-6-8-17(14)22/h5-10,12,26H,4H2,1-3H3,(H,25,27)/b16-13-

Standard InChI Key:  QBZIDOQSMDBJOR-SSZFMOIBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 386.40

Molecular Weight (Monoisotopic): 386.1442

AlogP: 5.10

#Rotatable Bonds: 6

Polar Surface Area: 82.35

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 5.71

CX Basic pKa:

CX LogP: 4.33

CX LogD: 2.64

Aromatic Rings: 2

Heavy Atoms: 28

QED Weighted: 0.41

Np Likeness Score: -1.15

References

1. Li C, Zhou Y, Xu J, Zhou X, Huang Z, Zeng T, Yang X, Tao L, Gou K, Zhong X, Chen Q, Luo Y, Zhao Y..  (2022)  A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.,  238  [PMID:35640328] [10.1016/j.ejmech.2022.114489]

Source

Source(1):

• Scientific Literature